Pacific Biosciences of California Inc (PACB) Stock Price, Trades & News

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Financial Strength

1/10

Name	Current	Vs Industry
Cash-To-Debt	0.39
Debt-to-Equity	297.29
Debt-to-EBITDA	-6.82
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-4.26	Distress Grey Safe
Beneish M-Score	-2.89	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

4/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-2.3
	3-Year EBITDA Growth Rate	26
	3-Year EPS without NRI Growth Rate	-9.9
	3-Year FCF Growth Rate	31.8
	3-Year Book Growth Rate	-80.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	13.13
	Future 3-5Y Total Revenue Growth Rate Estimate	9.33

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	86.77
	9-Day RSI	76.35
	14-Day RSI	68.58
	3-1 Month Momentum %	19.05
	6-1 Month Momentum %	-12.28
	12-1 Month Momentum %	16.28

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.65
	Quick Ratio	4.87
	Cash Ratio	4.22
	Days Inventory	190.68
	Days Sales Outstanding	72.67
	Days Payable	58.26

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-10.1
	Shareholder Yield %	19.12

Profitability Rank

2/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	37.49
	Operating Margin %	-111.9
	Net Margin %	-80.35
	EBITDA Margin %	-64.43
	FCF Margin %	-75.74
	OCF Margin %	-69.89
	ROE %	-326.45
	ROA %	-15.85
	ROIC %	-38.74
	3-Year ROIIC %	36.97
	ROC (Joel Greenblatt) %	-122.42
	ROCE %	-16.2
	Years of Profitability over Past 10-Year	1
	Moat Score	5
	Tariff Resilience Score	6

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	3.08
	PB Ratio	164
	EV-to-EBIT	-7.75
	EV-to-Forward-EBIT	-7.86
	EV-to-EBITDA	-9.09
	EV-to-Revenue	5.85
	EV-to-Forward-Revenue	5.86
	EV-to-FCF	-7.73
	Price-to-GF-Value	1.01
	Price-to-Median-PS-Value	0.41
	Earnings Yield (Greenblatt) %	-12.9
	FCF Yield %	-23.8

Financials (Next Earnings Date:2026-08-07 Est.)

Annual Quarterly TTM

PACB's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NAS:PACB

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Pacific Biosciences of California Inc Executives

Details

GF Value™: $1.62

PACB

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 6 Severe warning signs with PACB. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	160.03
	EPS (TTM) ($)	-0.43
	Beta	2.7008
	3-Year Sharpe Ratio	-0.34
	3-Year Sortino Ratio	-0.51
	Volatility %	102.52
	14-Day RSI	68.58
	14-Day ATR ($)	0.124014
	20-Day SMA ($)	1.45325
	12-1 Month Momentum %	16.28
	52-Week Range ($)	1.09 - 2.73
	Shares Outstanding (Mil)	310.6

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Pacific Biosciences of California Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Pacific Biosciences of California Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-11-05 16:30	In 129 days
Third quarter earnings results for 2026	2026-11-05	In 128 days
Second quarter earnings conference call for 2026	2026-08-07 17:00	In 39 days
Second quarter earnings results for 2026	2026-08-07	In 38 days
Jefferies’ Global Healthcare Conference	2026-06-04 14:00	1.58 (+0.64%)
General meeting for 2026	2026-06-03 09:00	1.58 (+1.94%)
First quarter earnings conference call for 2026	2026-05-07 16:30	1.71 (+8.23%)
First quarter earnings results for 2026	2026-05-07	1.71 (+8.23%)
TD Cowen\'s 46th Annual Health Care Conference	2026-03-02 14:30	1.68 (-3.17%)
Annual report for 2025	2026-02-25	1.66 (+5.06%)

Show

Entries

Pacific Biosciences of California Inc Frequently Asked Questions

What is Pacific Biosciences of California Inc(PACB)'s stock price today?

The current price of PACB is $1.64. The 52 week high of PACB is $2.73 and 52 week low is $1.09.

When is next earnings date of Pacific Biosciences of California Inc(PACB)?

The next earnings date of Pacific Biosciences of California Inc(PACB) is 2026-08-07 Est..

Does Pacific Biosciences of California Inc(PACB) pay dividends? If so, how much?

Pacific Biosciences of California Inc(PACB) does not pay dividend.

Guru Commentaries on NAS:PACB

No articles.

Press Release

	Subject	Date
	Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date	2025-06-02
	Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep	2024-10-30
	PACB Investors Have Opportunity to Join Pacific Biosciences of California, Inc. Fraud Investigation with the Schall Law Firm	2024-08-02
	PacBio and International Research Consortium CoLoRS Announce Release of First-Ever HiFi Long-Read Variant Database	2024-06-10
	Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases	2024-05-15
	Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases	2024-05-15
	PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance	2024-04-16
	Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes	2024-03-27
	PacBio Grants Equity Incentive Award to New Employee	2024-03-22
	PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions	2024-03-12

10/Page

Articles on Pacific Biosciences of California Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.